Cantor Fitzgerald Reduces Earnings Estimates for AxoGen

AxoGen, Inc. (NASDAQ:AXGN) – Investment analysts at Cantor Fitzgerald reduced their FY2024 EPS estimates for AxoGen in a research report issued to clients and investors on Tuesday, January 21st. Cantor Fitzgerald analyst R. Osborn now anticipates that the medical equipment provider will post earnings per share of ($0.58) for the year, down from their prior forecast of ($0.28). The consensus estimate for AxoGen’s current full-year earnings is ($0.30) per share. Cantor Fitzgerald also issued estimates for AxoGen’s FY2025 earnings at $0.19 EPS.

Separately, StockNews.com upgraded AxoGen from a “hold” rating to a “buy” rating in a research report on Tuesday, October 15th.

AxoGen Stock Performance

AXGN opened at $18.89 on Thursday. The business’s fifty day simple moving average is $15.40 and its 200 day simple moving average is $13.30. AxoGen has a 52 week low of $5.55 and a 52 week high of $19.03. The company has a debt-to-equity ratio of 0.67, a current ratio of 3.74 and a quick ratio of 2.47.

Hedge Funds Weigh In On AxoGen

Institutional investors and hedge funds have recently bought and sold shares of the stock. Quest Partners LLC raised its stake in shares of AxoGen by 23,066.7% during the third quarter. Quest Partners LLC now owns 2,085 shares of the medical equipment provider’s stock valued at $29,000 after acquiring an additional 2,076 shares during the last quarter. R Squared Ltd bought a new position in AxoGen during the 4th quarter valued at approximately $30,000. nVerses Capital LLC purchased a new stake in AxoGen in the 3rd quarter worth approximately $56,000. Oppenheimer & Co. Inc. bought a new stake in shares of AxoGen in the 3rd quarter worth approximately $156,000. Finally, Quantbot Technologies LP bought a new position in shares of AxoGen during the third quarter valued at approximately $165,000. 80.29% of the stock is currently owned by institutional investors.

AxoGen Company Profile

AxoGen, Inc, together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company’s products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries.